 | |
- close
- close
PR Newswire
Feb 4
Comment
MOUNTAIN VIEW, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Dr. Charles Bowden, senior director, clinical development, will present an overview of the company at the 12th Annual BIO CEO and Investor
MarketWatch
Jan 21
Comment
Investors in biotech group Vivus Inc. are betting heavily that its new anti-obesity drug Qnexa could be a game-changer in the weight-loss market, but some analysts caution that its approval isn’t necessarily a slam-dunk.
Globe Newswire
Jan 12
Comment
DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to
FierceBiotech
Jan 11
Comment
Vivus is reporting additional results from trial of its ED drug avanafil. Patients who attempted intercourse within 15 minutes of dosing were successful 67 percent, 69 percent and 72 percent of the time on 50, 100 and 200 mg of the drug,...
Market Intelligence Center
Jan 11
Comment
Vivus (NASDAQ: VVUS) opened at $10.83. So far today, the stock has hit a low of $10.49 and a high of $10.93. VVUS is now trading at $10.69, up $0.48 (4.7%). Over the last 52 weeks the stock has ranged from a low of $2.72 to a high of $12.88. VVUS...
MarketWatch
Jan 11
Comment
Drug stocks rise while shares of MAP Pharmaceuticals rally on news from U.S. regulators about its inhaled migraine headache treatment.
FierceBiotech
Jan 7
Comment
Shares of Vivus jumped in after-market trading after the developer unveiled new data that demonstrated its experimental obesity drug Qnexa significantly reduced sleep apnea in a mid-stage trial. Qnexa, which has attracted considerable attention in...
TheStreet.com
Jan 7
Comment
FDA will re-examine the safety of Amgen's anemia drugs, while Vivus' weight-loss drug posts win in small sleep apnea study.
StreetInsider.com
Jan 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/VIVUS+%28VVUS%29+To+Announce+Qnexa+Phase+2+Results+January+7%2C+2009/5227992.html for the full story.
MarketWatch
Dec 29
Comment
Chip maker Broadcom's shares slip late Tuesday after the company agrees to settle a lawsuit related to past stock-option accounting.
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| ||||||
